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Introduction: Our recent data showed that signal transducers and activators of transcription 1 (STAT1), adenosine
deaminase acting on RNA (ADAR), C-C motif chemokine ligand 2 (CCL2), and C-X-C motif chemokine 10 (CXCL10)
were significantly elevated in a systemic lupus erythematosus (SLE) cohort compared to healthy donors. High and
low STAT1 subsets were identified in SLE patient visits. The present study analyzed the correlation of common
treatments used in SLE with the levels of these biomarkers.
Methods: Peripheral blood leukocytes were collected from 65 healthy donors and 103 SLE patients, of whom 60
had samples from two or more visits. Total RNA was isolated and analyzed for the expression of mRNA and
microRNA using Taqman real-time polymerase chain reaction (PCR) assays. Relative expression of interferon
signature genes, CCL2, and CXCL10 were determined by the ΔΔCT method. Results were correlated with therapy
using prednisone, mycophenolate mofetil, and hydroxychloroquine and analyzed by Wilcoxon/Kruskal-Wallis test
and Fisher’s exact test.
Results: CCL2 and CXCL10 were significantly higher in untreated patients compared to treated patients, however,
in high STAT1 patient visits there is no significant difference between treated and untreated patients’ visits. When
comparing linear regression fits of interferon (IFN) score with CCL2 and CXCL10, untreated patients and high STAT1
patients displayed significantly higher slopes compared to treated patients. There was no significant difference
between the slopes of high STAT1 and untreated patients indicating that CCL2 and CXCL10 were correlated with
type-I IFN in high STAT1 patients similar to that in untreated patients. CCL2 and CXCL10 levels in the high STAT1
subset remained high in treated patient visits compared to those of the low STAT1 subset.
Conclusions: Among the biomarkers analyzed, only CCL2 and CXCL10 showed significantly reduced levels in
treated compared to untreated SLE patients. STAT1, CCL2, and CXCL10 are potentially useful indicators of
therapeutic action in SLE patients. Further work is needed to determine whether high STAT1 levels convey
resistance to therapies commonly used to treat SLE and whether STAT1 inhibitors may have therapeutic implication
for these patients.* Correspondence: echan@ufl.edu
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Systemic lupus erythematosus (SLE) is a systemic auto-
immune rheumatic disease affecting multiple systems and
organs in the body. Several genetic and environmental fac-
tors have been implicated in SLE etiopathogenesis. Even
though type I interferon (IFN-I: IFNα and IFNβ) was iden-
tified 30 years ago to be elevated in SLE patient serum, it
is only in recent years that its increased expression has
been rediscovered and postulated to play a key role in
disease pathogenesis in the majority of patients [1-4].
In addition to IFN-I, STAT1 (signal transducers and
activators of transcription 1), an interferon-inducible gene,
is involved in type I, II, and III IFN signaling and is re-
ported to be upregulated in SLE [5]. Besides STAT1,
interferon-regulated chemokines also play a role in SLE
pathogenesis [6]. C-C motif chemokine ligand 2 (CCL2)
and C-X-C motif chemokine 10 (CXCL10) have been im-
plicated in SLE as good indicators of potential flares [7].
The role of CCL2 in diseases such as psoriasis, rheumatoid
arthritis, and multiple sclerosis has incited additional
interest on its role in SLE [8]. Both CCL2 and CXCL10
depend upon the Jak/STAT pathway activation for induc-
tion by interferon [9-11] and these two chemokines were
identified as one of the 12 upregulated proteins in SLE [6].
The role of microRNAs (miRNAs) has also been impli-
cated in autoimmunity [12,13]. miR-146a was reported
to be underexpressed in peripheral blood mononuclear
cells of Chinese SLE patients [14]. The function of miR-
146a is now known to regulate innate immune response
and endotoxin tolerance [15-18]. miR-146a has also been
reported to be overexpressed in Sjögren’s syndrome [19],
psoriasis [20,21], and rheumatoid arthritis [22-24].
In an accompanying manuscript, we described high and
low STAT1 populations in SLE patients [25]. In the low
STAT1 population, levels of STAT1 correlated well with
IFN score; however, in the high STAT1 population they
did not. More importantly, high STAT1 patients displayed
elevated expression of CCL2 and CXCL10, but no signifi-
cant differences were observed for IFN score and tumor
necrosis factor alpha (TNFα) between high and low
STAT1. Finally, when the slope of the linear regression
representing the rate of change of CCL2 or CXCL10 per
unit of change of IFN score was analyzed, the slopes
of CCL2/IFN score and CXCL10/IFN score were signifi-
cantly greater in the high STAT1 patients compared to
the low STAT1 patients indicating that STAT1 poten-
tially enhanced CCL2 and CXCL10 response to IFN-I
[25].
The current therapies for SLE primarily aim to suppress
the inflammation and autoimmune response. Commonly
used therapies include prednisone (PDN), mycophenolate
mofetil (MMF), and hydroxychloroquine (HCQ). PDN is
a synthetic glucocorticoid that suppresses inflammation
by inhibiting nuclear factor kappa B (NF-кB). It inhibitsmonocyte and neutrophil inflammatory functions as well
as B and T cell responses [26]. Synthetic glucocorticoid,
such as dexamethasone and PDN can inhibit phospho-
rylation of STAT1 and potentially blocks IFN induction by
suppressing INF receptor (IFNAR) signaling [27]; however,
it has been shown that dexamethasone also upregulates
STAT1 transcription [27]. This inhibition of STAT1 func-
tion while increasing its transcription appears to be coun-
terintuitive but may represent a case of cell adapting to
compensate for the loss of functional STAT1. Increases in
STAT1 levels may lead to undesired consequences [28].
MMF is a cytotoxic drug commonly used to prevent organ
rejection after transplantation and also to treat auto-
immune diseases such as SLE. MMF is a reversible in-
hibitor of inosine monophosphate dehydrogenase that
blocks the de novo synthesis of guanosine nucleotides [29].
The latter is required for growth and proliferation of T
and B cells, as they lack the scavenger pathway and are
unable to compensate for the inhibition of de novo synthe-
sis of guanosine. Inhibition of T and B cell growth blocks
autoimmune response and leads to decrease in autoanti-
body production and T-cell-mediated tissue damage. The
antimalarial drug HCQ functions by increasing the pH of
endosomal vesicles. This disrupts antigen processing and
inhibiting toll-like receptor (TLR) 3, 7, 8, and 9 activity
[29-31]; furthermore, HCQ can inhibit macrophage pro-
duction of interleukin-1 and interleukin-6 [29]. Since
TLR7/9 have been implicated in inciting IFN-I production
due to recognition of self RNA/DNA, the blockade of
these TLRs could be attenuating IFN-I production and
antigen processing for presentation of T cells by antigen-
presenting cells such as dendritic cells.
In this study, we analyze differences in the expression
of various biomarkers, including STAT1, ADAR, CCL2,
CXCL10, and miR-146a, in SLE patients treated with
PDN, MMF, and HCQ versus untreated and healthy
donors.
Methods
Healthy donors and SLE patients
Patient information is as described in the accompanying
manuscript [25]. In brief, whole blood was collected from
a total of 103 SLE patients and 65 healthy donors enrolled
in the University of Florida Center for Autoimmune
Diseases registry from 2008 to 2011. Healthy donors were
selected based on no history of autoimmune disease,
while all SLE patients satisfied the American College of
Rheumatology criteria [32]. There were a total of 180 SLE
visits with sequential samples collected in 60 SLE patients
[25]. Healthy donors only visited the clinic once; therefore,
they represent a single visit. Among the total of 180 visits,
SLE patients were active in 49 visits according to the SLE
disease activity index (SLEDAI) score >4. All human blood
samples were obtained from enrolled individuals with the
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Florida. This study meets and is in compliance with all
ethical standards in medicine and informed consent was
obtained from all patients according to the Declaration of
Helsinki.
Data collection
RNA samples were isolated from peripheral blood leuko-
cytes for each patient visit and analyzed for gene expres-
sion using TaqMan real-time PCR assays as described in
the accompanying manuscript [25]. Anti-double-stranded
DNA (dsDNA) levels, C3 and C4 complement levels, IFN
score, and SLEDAI score were obtained as described [25].
C3 and C4 below 90 and 15 mg/dl, respectively, are con-
sidered subnormal levels.
Data analysis
TaqMan real-time PCR assays were used to measure gene
expression. The copy number of miR-146a was nor-
malized to total loaded RNA whereas mRNA levels were
normalized to 18S RNA. Copy number of miR-146a was
determined using a standard curve with synthetic miR-
146a (Integrated DNA Technologies Inc., Coralville, IA,
USA) [33]. Relative expression of mRNA was determined
by the ΔΔCT method [34]. SLE patients were primarily
treated with PDN, MMF, and/or HCQ. Correlations of all
therapies during each patient visit were analyzed with
levels of different SLE biomarkers. No patient in our SLE
cohort was treated with belimumab, a B-cell-activating
factor (BAFF) inhibitor approved by the FDA for SLE [35].
Analyses were performed using SAS version 9.2 and JMP
Genomics version 5 (SAS, Cary, NC, USA). Wilcoxon/
Kruskal-Wallis test was used to evaluate statistical sig-
nificance between groups. Fisher’s exact test was used to
examine the contingency between SLEDAI and therapy.
Normal distribution of IFN score, CCL2, and CXCL10 as
well as the bimodal distribution of STAT1 in SLE patients
and healthy donor (HD) visits was identified as described
in the accompanying manuscript [25]. Spearman Rho (ρ)
coefficient was used to determine monotonic associations
in the study. Coefficient of determination (r2) was used to
determine linear correlations. Significance between slopes
was evaluated by analysis of covariance (ANCOVA).
P values less than 0.05 were considered significant. The
Generalized Estimating Equation (GEE) model for repeated
measures was used to account for possible within subject
effects from patients with multiple visits [36].
Results
Comparison in the levels of various biomarkers in SLE
patient visits with or without treatment
Changes in C3, C4, and anti-dsDNA antibody levels in
SLE patient visits, and mRNA expression levels of va-
rious biomarkers in peripheral blood leucocytes wereexamined for possible effects of therapy (Figure 1). As
expected, SLEDAI (Figure 1A) and anti-dsDNA auto-
antibody (Figure 1D) levels were significantly lower in
treated (Tx) than untreated (UTX) patients, while C3
(Figure 1B) and C4 (Figure 1C) were significantly higher
in Tx than UTX patients. Overall, anti-dsDNA auto-
antibody, IFN scores, adenosine deaminase acting on
RNA (ADAR), STAT1, CCL2, and CXCL10, were signifi-
cantly lower in HD than either UTX or Tx SLE patient
visits (Figure 1D-I). However, there were no significant
differences among the groups for miR-146a (Figure 1J)
and TNFα (Figure 1L) expression. pri-miR-146a showed
significantly higher level only in UTX compared to HD.
Bimodal distribution of STAT1 in SLE patient and HD
visits was identified as described in the accompanying
manuscript [25]. To further elucidate the influence of high
and low STAT1 populations, UTX and HD from Figure 1
were further examined by comparing the high (blue) and
low (red) STAT1 groups (See Additional file 1: Figure S1).
As expected, regardless of STAT1 levels, UTX was signifi-
cantly higher in anti-dsDNA, IFN score, ADAR, CCL2,
and CXCL10 than HD (See Additional file 1: Figure S1A-
C,E,F) while there was no difference in STAT1, miR-146a,
pri-miR-146a, and TNFα (See Additional file 1: Figure
S1D, G-I). High STAT1 HD displayed higher levels of
STAT1, CCL2, and CXCL10 (See Additional file 1: Figure
S1D-F) than low STAT1 HD; however, for the remaining
biomarkers, there were no significant differences. Levels of
various biomarkers in UTX patient visits were not sig-
nificantly different by STAT1 levels with the exception of
STAT1 (See Additional file 1: Figure S1). Due to the lack
of significant difference in levels of biomarkers between
high and low STAT1 UTX patients, UTX were not sepa-
rated in any subsequent analysis.
Next, various biomarker levels in treated patients with
high versus low STAT1 visits were compared with UTX
and HD. Overall two very important outcomes became
apparent. First, the lack of significant difference between
UTX and high STAT1 for SLEDAI, IFN score, ADAR,
CCL2, and CXCL10 (See Additional file 1: Figure S2A-F,
H,I) potentially indicating that the pathology of high
STAT1 Tx patients resembled that of UTX patients. Sec-
ond, high STAT1 Tx patient visits displayed significantly
higher CCL2 and CXCL10 (See Additional file 1: Figure
S2H,I) than the low STAT group, which might be indica-
tors of increased pathological activity. miR-146a also
showed the same trend, however, high STAT1 Tx patients
have higher levels of miR-146a than UTX (See Additional
file 1: Figure S2J). Interestingly, pri-miR-146a appeared to
have an opposite trend (See Additional file 1: Figure S2K).
Comparison of individual therapies
Since many patients were on more than one medication,
we wanted to compare biomarkers in patients with an
Figure 1 Comparison in the levels of various clinical parameters and biomarkers in SLE patient visits with or without treatment.
(A) Disease activity, (B-C) complement levels, (D) anti-dsDNA antibody levels, (E) IFN score, (F) ADAR, (G) STAT1, (H) CCL2, (I) CXCL10, (J) miR-146a,
(K) pri-miR-146a, and (L). TNFα in treated (Tx) and untreated (UTX) SLE patient visits as well as healthy donors (HD). Data are presented as box plot. All
groups were compared among each other and only significant P values are shown indicating each specific comparison. Average trend lines for high
STAT1 (blue) and low STAT1 (red) patient visit subsets are also shown for comparison. Detail comparison between high and low STAT1 subsets are
shown in Additional file 1: Figure S2. ADAR, adenosine deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemo-
kine 10; dsDNA, double-stranded DNA; IFN, interferon; SLE, systemic lupus erythematosus; STAT1, signal transducer and activator of transcription 1;
TNFα, tumor necrosis factor alpha.
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tients not receiving PDN from the Tx group, there was
no statistical significant difference between PDN Tx and
UTX with SLEDAI, C3, and C4 (Figure 2A-C). However,
SLE patients receiving PDN were more frequently inactive
(P = 0.0071; likelihood ratio: 7.44) than active by SLEDAI
score. The remaining biomarkers (Figure 2D-L) showed
similar significant trends as seen in the Tx population
(Figure 1D-L), which might indicate that the overall re-
sults were from a combinatory effect of the therapy and/
or all therapy had similar effects on these biomarkers. To
appreciate these results, HCQ and MMF were also ana-
lyzed in the same manner (Figures 3 and 4). SLEDAI, C3,
and C4 were significantly different between HCQ patients
and UTX (Figure 3A-C); however, only SLEDAI and C4
were significantly different between MMF and UTX
patient visits (Figure 4A-C). The results for SLEDAI
were consistent with SLE patient visits treated with
HCQ (P = 0.0002; likelihood ratio: 13.9) or with MMF
(P <0.0001; likelihood ratio: 16.1) were more likely to be
in inactive states. The remaining biomarkers for HCQ
(Figure 3D-L) and MMF (Figure 4D-L) resembled those in
the entire Tx population (Figure 1D-L).
After establishing the basic role of high and low STAT1,
their correlation was further explored for each therapy.
Beginning with PDN, TNFα was significantly decreased in
the low STAT1 PDN patient visits relative to UTX and
HD; however, high STAT1 PDN patient visits were not
significantly different (See Additional file 1: Figure S3L).
This trend was not observed for either HCQ or MMF
patients (See Additional file 1: Figure S4L, S5L). High and
low STAT1 patients under PDN therapy (See Additional
file 1: Figure S3A-C) did not display any significant dif-
ferences for SLEDAI, C3, and C4, which resembled the
earlier results (Figure 2A-C). This differed for HCQ and
MMF where low STAT1 patient visits were significantly
lower than UTX patient visits for SLEDAI, and higher in
C3 and C4 (See Additional file 1: Figure S4A-C, 5A-C). In
PDN, HCQ, and MMF patient visits, CCL2 and CXCL10
was significantly elevated in the high STAT1 population
compared to the low STAT1, but significantly different
from UTX (See Additional file 1: Figures S3H,I; S4H,I;
S5H,I). This resembled what was observed earlier in high/
low STAT1 Tx patients (See Additional file 1: Figure S2H,I)
suggesting that high STAT1 patients might maintain high
levels of CCL2 and CXCL10 regardless of the therapy
used.
The relationship between miR-146a and pri-miR-146 was
particularly revealing when the analyses took into account
the difference in high STAT1 versus low STAT1 status.
While miR-146a did not show any significant difference in
PDN, HCQ, and MMF patient visits (Figures 2J, 3J and 4J),
high versus low STAT1 Tx patient visits (See Additional
file 1: Figure S2J) as well as patients treated with PDN,HCQ, and MMF (See Additional file 1: Figure S3J, S4J, S5J)
revealed that high STAT1 patient visits were significantly
higher in miR-146a than low STAT1 patient visits, UTX,
and HD. In contrast, pri-miR-146a levels were significantly
lower in high STAT1 patient visits than in low STAT1 pa-
tient visits, UTX, and HD for high/low STAT1 Tx patient
visits (See Additional file 1: Figure S2K) as well as patients
treated with PDN, HCQ, and MMF (See Additional file 1:
Figures S3K, S4K, S5K). The reverse trend seen between
pri-miR-146a and miR-146a was probably due to dif-
ferences in conversion from primary to mature miRNA or
potential differences in their intrinsic stability.
Therapy dosage could vary based on disease manifest-
ation and severity. To examine the effects of therapy
dosage, the PDN, MMF, and HCQ treated patients were
separated by dosage (Figure 5). As dosage increased so
did the levels of the biomarkers that are supposed to
correlate with disease activity. This might be attributed
to the way therapy was administered. As the disease ac-
tivity of patients became higher, prescription of higher
doses of therapy might be expected. Essentially, therapy
dosage might act as a marker of disease activity. Interes-
tingly, the high STAT1 patient visits (blue) appeared to
show higher levels of STAT1, CCL2 and CXCL10 than
in low STAT1 patient visits as therapy dose increased
(Figure 5, Additional file 1: Figure S6).
Association between CCL2, IFN score, and therapy
The accumulated evidence so far appeared that patients
with high levels of STAT1 were maintaining high CCL2
and CXCL10 expression even during therapy; we tested
how STAT1 levels affected the association of CCL2 and
CXCL10 with IFN score. Since CCL2 and CXCL10 are
known to be induced by interferon, this would suggest a
positive covariation where CCL2 and CXCL10 increase as
IFN score increases. The slope of CCL2/IFN score and
CXCL10/IFN score thus represents the association bet-
ween CCL2 and CXCL10 with IFN score. By comparing
the slope between groups, the effects of therapy on the as-
sociation of CCL2 and CXCL10 with IFN score could be
examined. For example, when the slope of CCL2/IFN
score was greater for UTX than that of a particular ther-
apy, it suggested that the decreased association in CCL2/
IFN score for the treated patients was a result of that par-
ticular therapy or due to other conditions of the patients.
When the association of CCL2 with IFN score was plot-
ted as shown in Figure 6A, three items were noted. First,
both UTX and Tx were monotonic and increased as ob-
served from the Spearman rho coefficient (ρ). Second,
both UTX and Tx displayed a linear component as
described by the coefficient of determination (r2) and
UTX had a greater linearity than Tx. Third, UTX had a
significantly greater slope for CCL2/IFN score than Tx
(P = 0.0002, black versus green line) potentially indicating
Figure 2 Comparison of the levels of various biomarkers in the SLE patient visits with prednisone (PDN) therapy versus untreated.
Data were analyzed as in Figure 1 except only patients receiving PDN in the treated patient population were included. (A) Disease activity,
(B-C) complement levels, (D) anti-dsDNA antibody levels, (E) IFN score, (F) ADAR, (G) STAT1, (H) CCL2, (I) CXCL10, (J) miR-146a, (K) pri-miR-146a,
and (L) TNFα in treated (Tx) and untreated (UTX) SLE patient visits as well as healthy donors (HD). Data are presented as box plot. All groups were
compared among each other and only significant P values are shown indicating each specific comparison. Average trend lines for high STAT1
(blue) and low STAT1 (red) patient visit subsets are also shown for comparison. Detail comparison between high and low STAT1 subsets are
shown in Additional file 1: Figure S3. ADAR, adenosine deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif
chemokine 10; dsDNA, double-stranded DNA; IFN, interferon; SLE, systemic lupus erythematosus; STAT1, signal transducer and activator of
transcription 1; TNFα, tumor necrosis factor alpha.
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Figure 3 Comparison of the levels of various biomarkers in the SLE patients visits with hydroxychloroquine (HCQ) therapy versus
untreated. Data were analyzed as in Figure 1 except only patients receiving HCQ in the treated patient population were included. (A) Disease activity,
(B-C) complement levels, (D) anti-dsDNA antibody levels, (E) IFN score, (F) ADAR, (G) STAT1, (H) CCL2, (I) CXCL10, (J) miR-146a, (K) pri-miR-146a, and
(L) TNFα in treated (Tx) and untreated (UTX) SLE patient visits as well as healthy donors (HD). Data are presented as box plot. All groups were compared
among each other and only significant P values are shown indicating each specific comparison. Average trend lines for high STAT1 (blue) and low STAT1
(red) patient visit subsets are also shown for comparison. Detail comparison between high and low STAT1 subsets are shown in Additional file 1: Figure S4.
ADAR, adenosine deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10; dsDNA, double-stranded DNA; IFN,
interferon; SLE, systemic lupus erythematosus; STAT1, signal transducer and activator of transcription 1; TNFα, tumor necrosis factor alpha.
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Figure 4 Comparison of the levels of various biomarkers in the SLE patients visits with mycophenolate mofetil (MMF) therapy versus
untreated. Data were analyzed as in Figure 1 except only patients receiving MMF in the treated patient population were included. (A) Disease
activity, (B-C) complement levels, (D) anti-dsDNA antibody levels, (E) IFN Score, (F) ADAR, (G) STAT1, (H) CCL2, (I) CXCL10, (J) miR-146a, (K) pri-miR-146a,
and (L) TNFα in treated (Tx) and untreated (UTX) SLE patient visits as well as healthy donors (HD). Data are presented as box plot. All groups were compared
among each other and only significant P values are shown indicating each specific comparison. Average trend lines for high STAT1 (blue) and low STAT1
(red) patient visit subsets are also shown for comparison. Detail comparison between high and low STAT1 subsets are shown in Additional file 1: Figure S5.
ADAR, adenosine deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10; dsDNA, double-stranded DNA; IFN,
interferon; SLE, systemic lupus erythematosus; STAT1, signal transducer and activator of transcription 1; TNFα, tumor necrosis factor alpha.
Dominguez-Gutierrez et al. Arthritis Research & Therapy 2014, 16:R23 Page 8 of 15
http://arthritis-research.com/content/16/1/R23
Figure 5 Comparison of the levels of various biomarkers in the SLE patient visits given PDN, MMF, and HCQ therapy at high or low
dosage. Differences between doses of PDN (D, G, J, M), MMF (B, E, H, K, N), and HCQ (C, F, I, L, O) were not significant with the exception of
SLEDAI (A), and in fact SLEDAI scores were higher for PDN dose of 20 to 60 mg/day compared to the 2 to 18 mg/day of dose. HCQ,
hydroxychloroquine; MMF, mycophenolate mofetil; PDN, prednisone; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.
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Figure 6 Association between CCL2, IFN score, and therapy. (A) The relationship of CCL2 versus IFN score presented as a slope was analyzed
in untreated (UTX, black) and treated SLE patient visits (Tx, green). Similar analyses were carried out for PDN-treated (C), MMF-treated (E), and
HCQ-treated patient visits (G) as well as for high STAT1 (blue) and low STAT1 (red) for Tx (B), PDN-treated (D), MMF-treated (F), and HCQ-treated
patient visits (H). CCL2, C-C motif chemokine ligand 2; HCQ, hydroxychloroquine; IFN, interferon; MMF, mycophenolate mofetil; PDN, prednisone;
SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; STAT1, signal transducer and activator of transcription 1.
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Figure 6B, Tx was segregated into high and low STAT1.
Similarly, high STAT1 Tx and low STAT1 Tx were mono-
tonic, increasing and linear. High STAT1 Tx displayed a
significantly higher slope than low STAT1 Tx (Figure 6B,
P <0.0001, blue versus red line) and significantly higher
slope than Tx (Figure 6A-B, P <0.0001, blue versus green
line) indicating that CCL2 responsiveness to IFN-I in high
STAT1 patients was more similar to that of the UTX
patients. Overall similar results were observed for PDN,
MMF, and HCQ (Figure 6C-H). The same analysis was
performed for CXCL10 (Figure 7). The results were simi-
lar to those of CCL2 (Figure 6) with the exception for
PDN and MMF in the high versus low STAT1 patient
visits (Figure 7D,F). For PDN, high STAT1 patient visits
were not significantly different than low STAT1 (blue ver-
sus red line); in addition, high STAT1 PDN was signifi-
cantly lower than UTX (Figure 7C-D, P = 0.0005, blue
versus black line) and this might indicate that PDN af-
fected CXCL10 response to IFN-1. For MMF, high STAT1
patient visits had significantly higher slope than low
STAT1 patient visits (Figure 7F, P = 0.038, blue versus red
line); however, high STAT1 MMF was not significantly
different in CXCL10 from MMF-treated patient visits
(Figure 7E-F, blue versus green line).
Expression of CCL2 and CXCL10 in high versus low STAT1
patient subsets with individual and combined therapy
Finally, all possible therapy combinations (MMF, PDN,
HCQ, HCQ+MMF, PDN+MMF +HCQ, PDN+MMF,
PDN +HCQ, and UTX) were compared for the expres-
sion of all biomarkers. Interestingly, while there was no
significant differences in IFN score, STAT1, ADAR, pri-
miR-146a, and mature miR-146a observed between UTX
and the various treatments (data not shown), CCL2 and
CXCL10 displayed significant trends (Figure 8). For nearly
every treatment, CCL2 was decreased compared to UTX
(Figure 8A). Overall significant decrease in CCL2 tran-
scripts in those treated compared to UTX patient visits in-
dicated that therapy was affecting CCL2 transcription;
however, this might not be true for high STAT1 patient
visits (blue line) as they were significantly higher in CCL2
than the low STAT1 patients (red line) for nearly every
treatment (Figure 8A). The low STAT1 patients appeared
to be responsive to therapy as they were significantly lower
than UTX and the majority was not significantly different
from HD (See Additional file 1: Figure S7A). This was
reversed in the high STAT1 patients where HD were
significantly lower than treated patients and the majority
were not significantly different from UTX patients (See
Additional file 1: Figure S7b).
The results for CXCL10 were not as consistent as
CCL2. UTX patients were significantly higher in CXCL10
than any treated groups (Figure 8B). Both the treatedpatient visits, high STAT1 patient visits, and the majority
of low STAT1 patient visits were significantly lower than
UTX (Figure 8A, Additional file 1: Figure S8). While the
low STAT1 patient visits were significantly lower in
CXCL10 than UTX, the high STAT1 were not significantly
different from UTX (See Additional file 1: Figure S8) po-
tentially again supporting that high STAT1 levels contri-
bute to maintain the high level of CXCL10 in patients
under therapy.
Discussion
Our study focused on the difference in the levels of SLE bio-
markers and their relationship with interferon, CCL2, and
CXCL10 in SLE patients given different therapy. IFN-I and
interferon signature genes were reported to be elevated both
at the mRNA level based on data from microarray analyses
and even at the protein level in the serum of SLE patients
[4,37-39]. Not surprisingly, our results reaffirm the elevated
expression of ADAR, STAT1, CCL2, and CXCL10 in SLE
patients [25] as reported in the literature [1,2,6,7,37,40].
CCL2 and CXCL10 levels are lower in treated versus
untreated SLE patients. The majority of SLE patient
visits were receiving therapy at the time of sample col-
lection. SLE patient visits using PDN, MMF, and HCQ
as well as therapy combinations displayed no significant
decrease of IFN score, STAT1, ADAR, pri-miR-146a,
and mature miR-146a compared to untreated. Linear
regression analyses treating the patient visits as inde-
pendent variables (in Figures 6 and 7) yielded essentially
the same conclusion when compared to using the GEE
model for repeated measures (data not shown).
PDN is a glucocorticoid that suppresses NF-кB signaling
[41]. It is unclear how or even if PDN suppresses IFN pro-
duction. Glucocorticoids have been reported to suppress
STAT1 phosphorylation (pSTAT1) [27], but depending
upon cell type and profile, they can also lead to changes in
the transcription of STAT1 [28,42]. STAT1 is important for
CCL2 and CXCL10 induction by INF [43-45]. Furthermore,
the decrease in pSTAT1 could explain why CCL2 and
CXCL10 decreased in the low STAT1 patients. The in-
crease in STAT1 expression may be an attempt to compen-
sate for decreased pSTAT1 levels and may possibly explain
the occurrence of the high STAT1 patients. This may also
be the reason for CCL2 and CXCL10 increase in high
STAT1 patients and why CCL2 and CXCL10 are not as sig-
nificantly lower in SLE patients undergoing therapy in the
high STAT1 patients compared to the low STAT1 patients.
On the other hand, CCL2 and CXCL10 expression
levels in SLE patients undergoing therapy were significant
lower than untreated patients. PDN has been previously
reported to decrease CCL2 and CXCL10 expression
[46-48]. If PDN reduces pSTAT1 levels, this may explain
in part the decrease of CCL2 and CXCL10 expression due
to the role of STAT1 in chemokine signaling [43-45]. In
Figure 7 Association between CXCL10, IFN score, and therapy. Data were analyzed as in Figure 6 except that CCL2 was substituted by
CXCL10. (A) The relationship of CCL2 versus IFN score presented as a slope was analyzed in untreated (UTX, black) and treated SLE patient visits
(Tx, green). Similar analyses were carried out for PDN-treated (C), MMF-treated (E), and HCQ-treated patient visits (G) as well as for high STAT1
(blue) and low STAT1 (red) for Tx (B), PDN-treated (D), MMF-treated (F), and HCQ-treated patient visits (H). CCL2, C-C motif chemokine ligand 2;
CXCL10, C-X-C motif chemokine 10; HCQ, hydroxychloroquine; IFN, interferon; MMF, mycophenolate mofetil; PDN, prednisone; SLE, systemic lupus
erythematosus; SLEDAI, SLE disease activity index; STAT1, signal transducer and activator of transcription 1.
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Figure 8 The expression of CCL2 and CXCL10 in high versus low STAT1 patient subsets with individual and combined therapy.
(A) CCL2 levels in HD (healthy donor), untreated (UTX), and other patient visits under treatment with different combinations of PDN, MMF, and HCQ
were plotted (black bars). Only significant differences comparing each treatment group to either HD or UTX are indicated as black lines with P value
shown. Data segregating into high STAT1 (blue line) and low STAT1 (red line) subsets are also shown and significant differences for these subsets are
indicated by green asterisks. (B) CXCL10 data were analyzed similarly. CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10; HCQ,
hydroxychloroquine; HD, healthy donor; IFN, interferon; MMF, mycophenolate mofetil; PDN, prednisone; SLE, systemic lupus erythematosus; SLEDAI,
SLE disease activity index; STAT1, signal transducer and activator of transcription 1.
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nificantly change from untreated SLE patients, possibly in-
dicating that the elevated levels of STAT1 are facilitating a
pathogenic pattern occurring in the untreated patients. In
part, STAT1 may be increasing to compensate for inhi-
bition of STAT1 phosphorylation and maintain CCL2 and
CXCL10 levels as in the untreated patients. STAT1 has
been associated with therapy resistance in cancer. STAT1
overexpression protects cancers from DNA-damaging
agents including radiation therapies and chemotherapies
in different cancer types [49]. Radioresistant nu61 derived
from radiosensitive SCC61 tumors displayed 49 ove-
rexpressed genes; of these 49 genes, 31 were ISGs also
including STAT1 [50]. Furthermore when STAT1 was
overexpressed in SCC61 cells, it displayed radioresistance
[51]. Similarly, human fibroblasts repeatedly exposed to
IFN-I displayed radio-resistance [52]. In 10 cancer cell
lines, STAT1 expression correlated with resistance to
doxorubicin and topoisomerase-II inhibitors [53]. In
addition, 14 ovarian cancer lines were observed for resis-
tance to platinum compounds where STAT1 was asso-
ciated with resistance to cisplatin and AMD473 [54].
These associations between therapy resistance and STAT1
in cancer may explain the association of STAT1 levels
with higher CCL2 and CXCL10 and the apparent lack of
therapy sensitivity in high STAT1 patients.
Conclusions
Increases in CCL2 and CXCL10 have been associated with
SLE patients entering a state of flare activity [6,7]. We
consider reduction of CCL2 and CXCL10 as good indica-
tors of successful therapy, while elevation in STAT1 levels
may indicate therapy resistance. Further work is needed to
determine the role that STAT1 plays in therapy, but thisstudy gives insight to a potentially new role for STAT1 in
SLE. Our study raises an interesting question whether SLE
patients with high STAT1 status can benefit from therapy
with specific STAT1 inhibitors [55].
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